
RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS

OUR CONTROLLING SHAREHOLDERS

As of the date of this Document, 6 Dimensions LP, 6 Dimensions Affiliates, Suzhou Frontline II and Suzhou 6 Dimensions will be interested in approximately 21.85%, 1.15%, 9.17% and 21.40% of the total issued share capital of our Company, respectively. The respective investment committee (the “**Investment Committee**”) of each of the 6 Dimensions Entities comprises of the same members, including Dr. Zhu Qingsheng, Dr. Li Wei, Mr. Hu Edward and Dr. Chen Lian Yong, our non-executive Director and chairman of the Board (individually and collectively, the “**Investment Committee Member(s)**”), which is the decision-making body of each of the 6 Dimensions Entities. The Investment Committee is the decision-making body of 6 Dimensions Capital (通和毓承) and is responsible for approving investment and divestment of all portfolio companies of the 6 Dimensions Entities. Each Investment Committee Member is entitled with one vote for matters presented in the meeting of the Investment Committee, and all resolutions resolved at such meeting shall be approved by a majority of the Investment Committee Members. The Investment Committee has the authority to make the ultimate investment decision on behalf of the 6 Dimensions Entities, and can override the decisions made by general partners thereof. The investment structure to our Company from 6 Dimensions Capital (通和毓承) through the 6 Dimension Entities as described under the section headed “History, Development and Corporate Structure – [REDACTED] Investments – Information about the [REDACTED] Investors – Controlling Shareholders” takes into account the internal investment policy of 6 Dimensions Capital (通和毓承) as well as investment terms and remaining [REDACTED] from each of the 6 Dimension Entities. Such investment structure is similar to other portfolio companies incubated by 6 Dimensions Capital (通和毓承).

Therefore, 6 Dimensions Entities, which will be in aggregate interested in approximately [REDACTED]% of the total issued share capital of our Company immediately after the completion of [REDACTED] (assuming the [REDACTED] is not exercised and no further Shares are issued under the [REDACTED] Equity Incentive Plan), will constitute a group of Controlling Shareholders upon [REDACTED]. For more details of 6 Dimensions Entities, see “History, Development and Corporate Structure – [REDACTED] Investments”.

6 Dimensions Capital (通和毓承) became acquainted with Ms. Zhang Lele in 2018 through common acquaintance, Dr. Xie Qin, one of our non-executive Directors who was then serving at an affiliate of 6 Dimensions Capital (通和毓承). For details, please refer to the section headed “History, Reorganization and Corporate Structure – Overview”. As a specialist healthcare private equity fund management company, 6 Dimensions Capital (通和毓承) has a track record of incubating companies focusing on various fields at healthcare industry. After in-depth communication, 6 Dimensions Capital (通和毓承) and Ms. Zhang Lele began exploring business opportunities in the dermatology treatment and care market, where they believe strong potentials existed. With confidence in the industry experience and management skills of Ms. Zhang Lele, our Group was founded in 2019 by 6 Dimensions Entities as shareholders of the Company and Ms. Zhang Lele, as our CEO and executive Director.

RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS

CLEAR DELINEATION OF BUSINESS

6 Dimensions Entities are investment funds managed under 6 Dimensions Capital (通和毓承), a specialist healthcare private equity fund management company with an in-depth focus on healthcare and extensive coverage across China and/or the United States. As of the Latest Practicable Date, 6 Dimensions Entities and their affiliates invested and cultivated a portfolio of more than 80 companies, including, among others, 111, Inc., CStone Pharmaceuticals, GRAIL, Inc., Hua Medicine, Ocumension Therapeutics, Viela Bio, Inc., IDEAYA Biosciences, Inc., TCR² Therapeutics, Inc., iTeos Therapeutics, Inc., Fulcrum Therapeutics, Inc. and Kymera Therapeutics, Inc..

As of the Latest Practicable Date, other than the interest in our Company, the Controlling Shareholders had controlling interests in the following companies:

Name of Company	Primary Business
Ocumension Therapeutics (歐康維視生物)	Identification development and commercialization of first- or best-in-class ophthalmic therapies
Curon Biopharmaceutical Limited	Development of next-generation tumor immunotherapy drugs
Shanghai WellVac Biotechnology Co., Ltd. (上海至成生物科技有限公司)	Research and development of human papillomavirus (HPV) vaccine
Shanghai Jiuben Technology Co., Ltd. (上海究本科技有限公司)	Development and commercialization of microbiome dietary intervention products and related technologies
Mabsoft Therapeutics (慕寶盛科)	Research and development of next-generation ADC for tumor immunotherapy
Shanghai Huazhou Pressure-sensitive Adhesive Products Co., Ltd. (上海華舟壓敏膠製品有限公司)	Development and production of medical pressure-sensitive adhesive products such as medical tapes, excipients, and band-aids

We are an R&D-driven, dermatology-focused biopharmaceutical company dedicated to developing innovative and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market.

RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS

To the best knowledge of our Directors, none of the Controlling Shareholders or their respective close associates holds 10% or more equity interests, individually or collectively, in any company whose products are the same as the Core Product and key products of our Company, or whose business competes or is likely to compete, directly or indirectly, with our business, that requires disclosure under Rule 8.10 of the Listing Rules.

INDEPENDENCE FROM OUR CONTROLLING SHAREHOLDERS

Having considered the following factors, our Directors are satisfied that we are able of carrying out our business independently from our Controlling Shareholders and their respective close associates after the [REDACTED].

Management Independence

Our business is managed and conducted by our Board and senior management. Our Board comprises two executive Directors, four non-executive Directors and three independent non-executive Directors. For more details, see “Directors and Senior Management”.

As of the Latest Practicable Date, Dr. Chen Lian Yong and Dr. Xie Qin, being non-executive Directors of our Company, are partners of 6 Dimensions Capital (通和毓承), the private equity fund management company under which our Controlling Shareholders are managed and act as directors, supervisors and/or advisors in companies invested by the Controlling Shareholders or their affiliated entities respectively. Other than above, there is no overlapping of directors or senior management between our Company and our Controlling Shareholders and their close associates.

Despite the aforementioned overlapping Directors, our Directors are of the view that our Board and senior management team are able to manage our business independently from the Controlling Shareholders and their respective close associates for the following reasons:

- Dr. Chen Lian Yong and Dr. Xie Qin as non-executive Directors are responsible for supervising the management of our Board, but are not involved in the day-to-day management or operations of our business. Therefore, their positions in the Controlling Shareholders or their close associates will not affect the day-to-day management of our business;
- each of our Directors is aware of his or her fiduciary duties as a Director which require, among others, that he or she must act for the benefit of and in the best interests of our Company and not allow any conflict between his or her duties as a Director and his or her personal interests;
- our daily management and operations are carried out by our executive Directors and an independent senior management team, all of whom have substantial experience in the industry in which our Company is engaged, and will therefore be able to make business decisions that are in the best interests of our Group;

RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS

- none other two non-executive Directors, our executive Directors and senior management team holds any directorships or management positions in, or represents interests of, our Controlling Shareholders;
- we have three independent non-executive Directors which (i) account for one-third of the Board; (ii) do not and will not hold any directorships or management positions in our Controlling Shareholders and (iii) possess requisite industry knowledge and experience and are qualified to provide independent, sound and professional advice to our Company;
- in the event that there is a potential conflict of interest arising out of any transaction to be entered into between our Group and our Directors or their respective associates, the interested Director(s) is required to declare the nature of such interest before voting at the relevant Board meetings of our Company in respect of such transactions; and
- we have adopted a series of corporate governance measures to manage conflicts of interest, if any, between our Group and our Controlling Shareholders and their close associates which would support our independent management. For more details, see “– Corporate Governance Measures”.

Based on the above, our Directors are satisfied that our Board as a whole together with our senior management team is able to perform the managerial role in our Group independently.

Financial Independence

Our Group has an independent financial system. We make financial decisions according to our own business needs and neither our Controlling Shareholders nor their close associates intervene with our use of funds. In addition, we have also established an independent finance department as well as implemented sound and independent audit, accounting and financial management systems.

As of the Latest Practicable Date, there were no outstanding loans or guarantees provided by, or granted to, our Controlling Shareholders or their respective close associates.

Our Directors believe that, upon [REDACTED], our Company will be able to obtain further financing, if necessary, upon market terms and conditions without relying on financial assistance or credit support from our Controlling Shareholders or their close associates.

Based on the above, our Company considers there is no financial dependence on our Controlling Shareholders or their close associates.

RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS

Operational Independence

We have full rights to make all decisions on, and to carry out, our own business operations independently. Our Company, through our subsidiaries, holds the licenses and qualifications necessary to carry on our current business, and has sufficient capital, facilities, technology and employees to operate the business independently from our Controlling Shareholders. We have access to third parties independently from and not connected to our Controlling Shareholders for sources of suppliers and customers. Based on the above, our Directors are of the view that we are able to operate independently from our Controlling Shareholders and their close associates.

CORPORATE GOVERNANCE MEASURES

Our Directors recognize the importance of good corporate governance in protecting our Shareholders’ interests. We have adopted the following measures to safeguard good corporate governance standards and to avoid potential conflict of interests between our Group and our Controlling Shareholders:

- under the Articles of Association, where a Shareholders’ meeting is to be held for considering proposed transactions in which any of our Controlling Shareholders or any of their associates has a material interest, the Controlling Shareholders or their associates will not vote on the relevant resolutions;
- our Company has established internal control mechanisms to identify connected transactions. If our Company enters into connected transactions with our Controlling Shareholders or any of their associates upon [REDACTED], our Company will comply with the applicable Listing Rules;
- the independent non-executive Directors will review, on an annual basis, whether there are any conflicts of interests between our Group and our Controlling Shareholders (the “**Annual Review**”) and provide impartial and professional advice to protect the interests of our minority Shareholders;
- our Controlling Shareholders will undertake to provide all information necessary, including all relevant financial, operational and market information and any other necessary information as required by the independent non-executive Directors for the Annual Review;
- our Company will disclose decisions on matters reviewed by the independent non-executive Directors either in its annual reports or by way of announcements as required by the Listing Rules;
- where our Directors reasonably request the advice of independent professionals, such as financial advisers, the appointment of such independent professionals will be made at our Company’s expenses; and

RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS

- we have appointed Somerley Capital Limited as our compliance advisor to provide advice and guidance to us in respect of compliance with the applicable laws and regulations, as well as the Listing Rules, including various requirements relating to corporate governance.

Based on the above, our Directors are satisfied that sufficient corporate governance measures have been put in place to manage conflicts of interest that may arise between our Group and our Controlling Shareholders, and to protect our minority Shareholders’ interests after [REDACTED].